Carsten Rudolph
Chief Executive Officer Ethris
Seminars
Wednesday 28th January 2026
Development of ETH47 for the Treatment of Asthma
12:30 pm
- Explore how Ethris is developing ETH47, a first-in-class mRNA-based nasal spray treatment for uncontrolled asthma, using their proprietary SNIM®RNA and SNaP LNP® technology platforms
- Discuss how ETH47 encodes interferon lambda (IFNλ), aiming to boost innate immune defense in the airways and address viral triggers of asthma exacerbations, with Phase 1 trials showing good safety and target engagement
- Discover how a Phase 2 clinical trial is underway to evaluate ETH47’s effectiveness in reducing asthma symptoms after a rhinovirus challenge in adults with asthma
